Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galantamine Flexible Dose in Alzheimer's Disease
NCT00253227Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Jul 1997
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
01
Overview
A Phase 3 trial of galantamine in Alzheimer's disease (AD), sponsored by Johnson & Johnson. Started Jul 1997; status: completed.
02
Drugs
galantamine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00253227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00253227.